Abstract

Parallel Tracking i-biomarker™ Development with Drug Development for Maximum Benefit

Kevin Cox, Chief Executive Officer, Imanova Limited

Molecular imaging is increasingly being used to support decision making in early-stage drug development, particularly in the CNS. Providing invaluable information on the so-called ‘three pillars of drug survival’, namely tissue delivery, target engagement and pharmacological effect, it can be seen as a kind of precision pharmacology. However, a lack of appreciation of when and how to use imaging and a lack of suitable tools means imaging is often an afterthought and employed in a post mortem of drug failure. Timely development of imaging biomarkers will ensure the full translational value of this technology can be realised This talk will illustrate, with case studies, how appropriate and timely use of imaging biomarkers can significantly reduce the risk, cost and time of drug development. Key benefits: • Learn how imaging can reduce risk, time and cost in drug development • Imaging what and when • A novel approach to imaging biomarker development • The future of imaging in drug discovery and development